Dalton Gooding, Ostrich

From the redoubtable Vesna Poljak in the AFR: http://www.copyright link/business/key-quintis-figures-also-served-on-santalis-board-20170614-gwqz20

​

Quintis chairman Dalton Gooding and former managing director Frank Wilson are current and former members respectively of the board of Santalis, the pharmaceutical arm at the centre of a disclosure breakdown within Quintis.​

​

...​

​

Based on statements by Quintis, it is apparent that the "communication breakdown" – as Mr Gooding has previously described it – occurred at the management level of Santalis.​

​

Quintis has reiterated in responses to the ASX that no current board member or senior manager, including Mr Gooding, was aware of Galderma's exit until May. This is despite the company not having shipped any of its sustainably grown pharmaceutical grade Indian sandalwood oil to Galderma since June 2015, a procedure for regular communication between Santalis and Quintis, and the Santalis chief executive attending Quintis board meetings in Perth in June 2016 and February 2017.​

This also appears to be the case despite Mr Gooding and Mr Wilson serving or having served on the board of Santalis itself.​

​

...​

​

San Antonio, Texas-based Santalis holds quarterly board meetings; Quintis chief executive Julius Matthys is now a member of the board as a function of him being the head of Quintis. The Quintis chairman and senior management of Santalis represent the rest of the board.​

As a member of the board of Santalis, how could Dalton Gooding not have known the contract had been terminated?

​